Both drugmakers shared aging clock data at a Boston longevity conference. Novo's study drew blood from 10,052 people, and aging clock inventor Steve Horvath called the effect strong.
Recap by typeshit. Full story at MIT Technology Review.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
The FDA says retatrutide falls one alpha amino acid short. A biologic label would mean 12 years of exclusivity instead of 5, a later Medicare price clock and no compounding.
Johns Hopkins researchers report in Annals of Internal Medicine that the pill drew in new patients rather than pulling them away from injectable Wegovy or Zepbound.
Loading…